Published On: Wed, Oct 19th, 2016

Upgrades And Downgrades For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)


Recently stock market analysts have updated their consensus ratings on shares of Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH).

Most recent broker ratings

06/29/2015 – Kythera Biopharmaceuticals, Inc. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 65 price target on the stock.

06/09/2015 – Guggenheim began new coverage on Kythera Biopharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 64 price target on the stock.

04/10/2015 – Bank of America Merrill Lynch began new coverage on Kythera Biopharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 66 price target on the stock.

11/11/2014 – Kythera Biopharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 59 price target on the stock.

Kythera Biopharmaceuticals, Inc. has a 50 day moving average of 74.78 and a 200 day moving average of 62.97.It has a 52-week low of 29.86 and a 52-week high of 76.31.

The share price of the company (NASDAQ:KYTH) was up +0.00% during the last trading session, with a high of 0.00 and the volume of Kythera Biopharmaceuticals, Inc. shares traded was 0.

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company’s initial focus is on the facial aesthetics market. The Company’s product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.